Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Heart Failure A Key Future Market For Jardiance?

EMPEROR-Reduced Underscores SGLT2 Benefits

Sep 02 2020

• By John Davis

Heart_Failure — • Source: Shutterstock

Related Content

DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front

Aug 31 2020

Jardiance Drives Boehringer Ingelheim Through First Half, Market Volatility Expected To Continue

Aug 04 2020

AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure

May 06 2020

Related Companies

Boehringer Ingelheim GmbH

Eli Lilly and Company

AstraZeneca PLC

Additional Topics

Clinical Trials Research & Development Market Intelligence Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.